Merck's new cholesterol combo faces delay

Merck's ($MRK) bid to get a combination Zetia-Lipitor cholesterol pill on the market faces a new hurdle. The FDA wants to see more data on the pill. The company hopes ongoing studies will fill that gap, because it needs a new entry to combat shrinking use of its previous Zetia combo, Vytorin. Report